Ming-Chih Liu

1.8k total citations
17 papers, 883 citations indexed

About

Ming-Chih Liu is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Ming-Chih Liu has authored 17 papers receiving a total of 883 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 11 papers in Genetics and 7 papers in Molecular Biology. Recurrent topics in Ming-Chih Liu's work include Acute Myeloid Leukemia Research (15 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers) and RNA modifications and cancer (3 papers). Ming-Chih Liu is often cited by papers focused on Acute Myeloid Leukemia Research (15 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers) and RNA modifications and cancer (3 papers). Ming-Chih Liu collaborates with scholars based in Taiwan, United States and Czechia. Ming-Chih Liu's co-authors include Wen‐Chien Chou, Hwei‐Fang Tien, Mei‐Hsuan Tseng, Jih‐Luh Tang, Hsin‐An Hou, Ming Yao, Bor‐Sheng Ko, Chien‐Yuan Chen, Shang‐Ju Wu and Shang‐Yi Huang and has published in prestigious journals such as Blood, EBioMedicine and BMC Infectious Diseases.

In The Last Decade

Ming-Chih Liu

15 papers receiving 865 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ming-Chih Liu Taiwan 12 645 410 271 136 131 17 883
Richard Dillon United Kingdom 15 531 0.8× 227 0.6× 174 0.6× 84 0.6× 4 0.0× 73 760
M. Alcorn United Kingdom 14 420 0.7× 131 0.3× 139 0.5× 15 0.1× 12 0.1× 23 678
Kazuaki Yakushiji Japan 10 113 0.2× 67 0.2× 43 0.2× 22 0.2× 23 0.2× 18 387
Shaun Fleming Australia 14 412 0.6× 302 0.7× 117 0.4× 41 0.3× 2 0.0× 56 815
Jess F. Peterson United States 15 228 0.4× 205 0.5× 113 0.4× 72 0.5× 14 0.1× 83 584
Rob S. Sellar United Kingdom 11 300 0.5× 154 0.4× 135 0.5× 54 0.4× 7 0.1× 22 482
D Manor Israel 7 369 0.6× 170 0.4× 248 0.9× 14 0.1× 7 0.1× 18 688
DR Head United States 9 519 0.8× 236 0.6× 144 0.5× 45 0.3× 5 0.0× 14 890
Catherine Tribouley United States 8 87 0.1× 184 0.4× 68 0.3× 30 0.2× 17 0.1× 14 495
Frank Stegelmann Germany 11 301 0.5× 318 0.8× 300 1.1× 21 0.2× 9 0.1× 37 619

Countries citing papers authored by Ming-Chih Liu

Since Specialization
Citations

This map shows the geographic impact of Ming-Chih Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming-Chih Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming-Chih Liu more than expected).

Fields of papers citing papers by Ming-Chih Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ming-Chih Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming-Chih Liu. The network helps show where Ming-Chih Liu may publish in the future.

Co-authorship network of co-authors of Ming-Chih Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Ming-Chih Liu. A scholar is included among the top collaborators of Ming-Chih Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ming-Chih Liu. Ming-Chih Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Lin, Chien‐Chin, Cheng‐Hong Tsai, Feng‐Ming Tien, et al.. (2025). Epidemiology, Treatment Outcomes, and Prognosis of Myelodysplastic Syndromes/Neoplasms in Taiwan: Real-World Insights and Trends. Clinical Lymphoma Myeloma & Leukemia. 25(6). e336–e347.e14.
2.
Tien, Feng‐Ming, Chi‐Yuan Yao, Cheng‐Hong Tsai, et al.. (2024). Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations. Blood Cancer Journal. 14(1). 8 indexed citations
3.
Lin, Chien‐Chin, Cheng‐Hong Tsai, Feng‐Ming Tien, et al.. (2024). Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms. Blood Cancer Journal. 14(1). 57–57. 7 indexed citations
4.
Tsai, Cheng‐Hong, Feng‐Ming Tien, Mei‐Hsuan Tseng, et al.. (2023). Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification. Blood Cancer Journal. 13(1). 120–120. 12 indexed citations
5.
Tsai, Cheng‐Hong, Feng‐Ming Tien, Yuan‐Yeh Kuo, et al.. (2023). Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML. Blood Cancer Journal. 13(1). 4–4. 17 indexed citations
6.
Lin, Chien‐Chin, Cheng‐Hong Tsai, Feng‐Ming Tien, et al.. (2023). Clinico-Genetic and Prognostic Analyses of 635 Patients with Myelodysplastic Neoplasms Based on the 2022 World Health Organization Classification. Blood. 142(Supplement 1). 1878–1878. 1 indexed citations
7.
Tsai, Cheng‐Hong, Jih‐Luh Tang, Feng‐Ming Tien, et al.. (2021). Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML. Blood Advances. 5(10). 2456–2466. 38 indexed citations
8.
Tsai, Cheng‐Hong, Chi‐Yuan Yao, Jih‐Luh Tang, et al.. (2019). Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients. EBioMedicine. 40. 240–250. 26 indexed citations
9.
Hou, Hsin‐An, Cheng‐Hong Tsai, Chien‐Chin Lin, et al.. (2018). Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome. Blood Cancer Journal. 8(4). 39–39. 66 indexed citations
10.
Hou, Hsin‐An, Cheng‐Hong Tsai, Shang‐Ju Wu, et al.. (2018). Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome. Clinical Epigenetics. 10(1). 42–42. 35 indexed citations
11.
Wu, Shang‐Ju, Jih‐Luh Tang, Chien‐Ting Lin, et al.. (2013). Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression. American Journal of Hematology. 88(11). E277–82. 48 indexed citations
12.
Wu, Shang‐Ju, Yuan‐Yeh Kuo, Hsin‐An Hou, et al.. (2012). The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood. 120(15). 3106–3111. 109 indexed citations
13.
Wei, Sung‐Hsi, Yuan-Pin Huang, Ming-Chih Liu, et al.. (2011). An outbreak of coxsackievirus A6 hand, foot, and mouth disease associated with onychomadesis in Taiwan, 2010. BMC Infectious Diseases. 11(1). 346–346. 147 indexed citations
14.
Hou, Hsin‐An, Tai‐Chung Huang, Liang‐In Lin, et al.. (2010). WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood. 115(25). 5222–5231. 111 indexed citations
15.
Tang, Jih‐Luh, Liang‐In Lin, Chien‐Yuan Chen, et al.. (2009). AML1/RUNX1 Mutations in 470 Adult Patients with De Novo Acute Myeloid Leukemia: Prognostic Implication and Interaction with Other Gene Alterations.. Blood. 114(22). 1564–1564. 14 indexed citations
16.
Tang, Jih‐Luh, Hsin‐An Hou, Chien‐Yuan Chen, et al.. (2009). AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood. 114(26). 5352–5361. 240 indexed citations
17.
Hou, Hsin‐An, Wen‐Chien Chou, Chien‐Yuan Chen, et al.. (2007). Characterization of Acute Myeloid Leukemia with PTPN11 Mutation - The Mutation Is Closely Associated with NPM1 Mutation but Inversely Related to FLT3/ITD.. Blood. 110(11). 3490–3490. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard Dillon Breakdown of academic impact, for papers by M. Alcorn Breakdown of academic impact, for papers by Kazuaki Yakushiji Breakdown of academic impact, for papers by Shaun Fleming Breakdown of academic impact, for papers by Jess F. Peterson Breakdown of academic impact, for papers by Rob S. Sellar Breakdown of academic impact, for papers by D Manor Breakdown of academic impact, for papers by DR Head Breakdown of academic impact, for papers by Catherine Tribouley Breakdown of academic impact, for papers by Frank Stegelmann
Rankless by CCL
2026